Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Localized vs. Systemic Pembrolizumab in Advanced Solid Tumors
NCT03755739Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2018
- Primary completion
- Nov 2033
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in hepatocellular carcinoma (HCC), lung cancer, melanoma and 7 more, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Nov 2018; status: recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)lung cancermelanomarenal cell carcinoma (RCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT03755739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755739.